Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Johns Hopkins University National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT00709007 |
Though the HIV epidemic in India is predominantly among heterosexual populations, it is estimated that there are approximately 1.1 million injection drug users (IDUs) in India with HIV prevalence as high as 64% among IDUs in certain cities. In April 2004, the government of India launched a free-antiretroviral therapy roll-out program aimed at initiating 100,000 persons on HAART. Similar guidelines are currently being followed for the delivery and choice of HAART for IDU and non-IDU populations. However, IDUs have certain issues that complicate the delivery of HAART that need to be addressed by delivery programs such as delayed access to care, poor perceived adherence, and more rapid disease progression. This proposal will assess the feasibility and effectiveness of directly administered antiretroviral therapy (DAART) in conjunction with opioid substitution as a mode of delivery of HAART to IDUs in Chennai, India. To evaluate this objective we will conduct a randomized controlled pilot study of DAART vs self-administered therapy (SAT) among 100 HIV-1 infected treatment naïve IDUs who are enrolled in an opioid substitution program in Chennai and compare the following outcomes between the two arms: Primary Endpoint: Proportion of participants with viral load (VL) <400 copies/ml at 24 and 48 weeks; Secondary Endpoints: (1) Incidence of mortality and AIDS-defining illnesses at 24 and 48 weeks, (2) Changes in absolute CD4+ count from baseline at 24 and 48 weeks, and (3) Incidence of antiretroviral drug resistance at 24 and 48 weeks. Intention-to-treat analyses will be used. The study objective is in line with the priority areas identified in the Indian National AIDS Control Program Phase III (NACP III) and the results of this study will help inform the government of India on appropriate modes of delivery of HAART to IDUs. This study will also be among the first studies to be conducted in India to evaluate two different modes of delivery of HAART to IDUs.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Heroin Dependence |
Behavioral: Directly Administered Antiretroviral Therapy (DAART) Behavioral: SAT |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Evaluating the Role of Directly Administered Antiretroviral Therapy (DAART) in Conjunction With Opiate Substitution in Delivery of Highly Active Antiretroviral Therapy to HIV-1-Infected Injecting Drug Users (IDUs) in Chennai, India |
Estimated Enrollment: | 100 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
DAART: Experimental
Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
|
Behavioral: Directly Administered Antiretroviral Therapy (DAART)
Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
|
SAT: Active Comparator
Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
|
Behavioral: SAT
Participants take their HIV medications by themselves.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
If female of childbearing potential (all of the following)
Satisfy Indian National Guidelines for initiation of HAART (any of the following)
Exclusion Criteria:
India, Tamil Nadu | |
YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR) | |
Chennai, Tamil Nadu, India, 600013 |
Principal Investigator: | Gregory M Lucas, MD,PhD | Johns Hopkins University School of Medicine, USA |
Responsible Party: | Johns Hopkins University School of Medicine ( Gregory M Lucas ) |
Study ID Numbers: | R01-DA018577-03S1 |
Study First Received: | July 1, 2008 |
Last Updated: | July 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00709007 |
Health Authority: | India: Indian Council of Medical Research; India: Institutional Review Board; United States: Institutional Review Board |
Sexually Transmitted Diseases, Viral Heroin Dependence Acquired Immunodeficiency Syndrome Disorders of Environmental Origin Opioid-Related Disorders Immunologic Deficiency Syndromes Virus Diseases |
Buprenorphine HIV Infections Mental Disorders Sexually Transmitted Diseases Substance-Related Disorders Retroviridae Infections |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |